Treatment of advanced renal cell carcinoma with axitinib: association of pharmacokinetics with treatment outcome and adverse events.

Trial Profile

Treatment of advanced renal cell carcinoma with axitinib: association of pharmacokinetics with treatment outcome and adverse events.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Feb 2017

At a glance

  • Drugs Axitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 18 Feb 2017 Results assessing genetic polymorphisms related to the Axitinib pharmacokinetics presented at the 2017 Genitourinary Cancers Symposium
    • 10 May 2016 Results of biomarker study (exosomal microRNAs and serum cytokines) presented at the 111th Annual Meeting of the American Urological Association
    • 10 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top